Article
Leading Epidemiologist Marianne Cunnington Joins Analysis Group from the Pharmaceutical Industry
Analysis Group is pleased to welcome Dr. Marianne Cunnington to its London office as a Vice President. Dr. Cunnington has two decades of experience as a pharmaceutical industry epidemiologist, specializing in the generation of real-world evidence (RWE) in support of the development of pharmaceutical and vaccine products, regulatory risk management strategies, and product risk-benefit assessments. Her experience with regulatory agencies in the US, the UK, Europe, and Asia includes new product registration submissions, post-approval safety studies, and post-marketing requirements and commitments. She has presented at over 40 international conferences, and her research has been published in many peer-reviewed journals. Prior to joining Analysis Group, Dr. Cunnington was accountable for regulatory real-world safety studies at GSK. She also has extensive experience leading industry epidemiology functions. Dr. Cunnington holds a Ph.D. in infectious disease epidemiology from the London School of Hygiene & Tropical Medicine and an M.Phil. in epidemiology from the University of Cambridge.
Meet Our People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and life cycle management of pharmaceutical and vaccine products, with a particular focus on regulatory risk management strategies and product benefit-risk assessments. Dr. Cunnington’s research expertise includes the design, negotiation, and execution of real-world components of risk management plans for new product submission to regulators in the US, UK, EU, Japan, and South Korea, including studies of post-approval safety in the EU; post-marketing requirements and commitments in the US; and pregnancy registries. Prior to joining Analysis Group, she served in several senior epidemiology positions at pharmaceutical companies, including as the chair of GSK’s peer review forum for all pharmaceutical RWE projects; as a member of GSK’s Global Safety Board; as head of epidemiology at Novartis Vaccines; and as a managing board member of Innovative Medicines’ public-private partnership initiative to build an integrated European real-world data (RWD) network to monitor medication safety in pregnancy.